Yiren Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yiren Yang has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Aimin Jiang
Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China
1 shared publication - Anqi Lin
Department of Oncology Zhujiang Hospital, The First School of Clinical Medicine, Southern Medical University; Donghai County People's Hospital (Affiliated Kangda College of Nanjing Medical University) Lianyungang China
1 shared publication - Hanzhong Zhang
Department of Urology, Changhai Hospital, Naval Medical University (Second Military Medical University), Shanghai, China
1 shared publication Jiatao Hu
Department of Urology, Changhai Hospital, Naval Medical University (Second Military Medical University), Shanghai, China
1 shared publicationJinxin Li
Department of Urology, Changhai Hospital, Naval Medical University (Second Military Medical University), Shanghai, China
1 shared publicationLe Qu
Department of Urology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China
1 shared publication
Latest Publications
- Open Access
- 3 February 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (4) , 10311-10326
Insights into the mechanisms of drug resistance in renal cell carcinoma: from multi-omics perspective
Renal cell carcinoma (RCC) is a prevalent malignancy of the urinary system. Despite significant advances achieved through targeted therapies and immunotherapies, therapeutic resistance remains a major obstacle to sustained clinical efficacy. This review comprehensively examines the molecular mechanisms driving resistance to both targeted therapy and immunotherapy in RCC from a multi-omics perspective. By integrating findings across diverse omics layers, we underscore the pivotal role of multi-level regulatory networks in mediating drug resistance and immune evasion. Our objective is to provide an in-depth understanding of these resistance mechanisms and to establish a theoretical framework for developing innovative therapeutic strategies aimed at overcoming resistance, thereby facilitating the advancement of precision oncology in RCC.
- 3 February 2026
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 112 (4) , 10311-10326
Open AccessInsights into the mechanisms of drug resistance in renal cell carcinoma: from multi-omics perspective
Renal cell carcinoma (RCC) is a prevalent malignancy of the urinary system. Despite significant advances achieved through targeted therapies and immunotherapies, therapeutic resistance remains a major obstacle to sustained clinical efficacy. This review comprehensively examines the molecular mechanisms driving resistance to both targeted therapy and immunotherapy in RCC from a multi-omics perspective. By integrating findings across diverse omics layers, we underscore the pivotal role of multi-level regulatory networks in mediating drug resistance and immune evasion. Our objective is to provide an in-depth understanding of these resistance mechanisms and to establish a theoretical framework for developing innovative therapeutic strategies aimed at overcoming resistance, thereby facilitating the advancement of precision oncology in RCC.